• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

byBryant LimandKiera Liblik
March 17, 2023
in Chronic Disease, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis.

2. The incidence of serious adverse events was not significantly different between the bedaquiline-linezolid regimen and standard treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The current standard of treatment for tuberculosis is a six-month rifampin-based regimen. While it is effective in clinical trials, difficulty with long-term treatment adherence has led to reduced efficacy in real-world program implementation. In addition, at least 85% of clinical trial participants are cured within three to four months of treatment. The entire six-month regimen may lead to overtreatment in most patients. In this noninferiority open-label randomized control trial, initial therapy with two eight-week regimens followed by extended treatment for persistent clinical disease, monitoring after treatment, or retreatment for relapse was compared with a standard 24-week regimen for adult patients with tuberculosis. The two eight-week regimens were rifampin-linezolid or bedaquiline-linezolid combined with isoniazid, pyrazinamide, and ethambutol. Patients were followed for 96 weeks. For the primary outcome, a composite of death or ongoing tuberculosis treatment or active tuberculosis by week 96, the noninferiority criterion was met for the group with an initial bedquiline-linezolid regimen and not for the group with an initial rifampin-linezolid regimen. The shorter duration regimens also had a positive effect on participant motivation to adhere to treatment. As a limitation, this was an open-label design, which may introduce treatment bias.

Click to read the study in NEJM

Relevant Reading: Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

RELATED REPORTS

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

Food compounds associated with disease activity in inflammatory bowel disease 

2 Minute Medicine Rewind June 23, 2025

In-Depth [randomized controlled trial]: In this noninferiority, open-label, randomized controlled trial, adult patients (n = 675) with nucleic acid amplification test or radiograph-confirmed tuberculosis were randomized to receive one of four eight-week initial treatment regimens [rifampin-linezolid (n=184); bedaquiline-linezolid (n=189); rifapentine-linezolid (n=78); rifampin-clofazimine (n = 42)] or standard treatment (n=181). The rifapentine-linezolid and rifampin-clofazimine groups did not achieve complete enrollment. For the eight-week initial regimens, treatment was continued for persistent or relapse of clinical disease. Patients were followed for 96 weeks. For the primary outcome, a composite of death, ongoing treatment, or active disease at 96 weeks, the noninferiority criterion compared to the standard treatment (3.9%) was not met in the rifampin-linezolid group (11.4% adjusted difference; 7.4 percentage points; 97.5% Confidence Interval [CI], 1.7 to 3.2) and met in the bedquiline-linezolid group (5.8% adjusted difference; 0.8 percentage points; 97.5% CI -3.4 to 5.1). For the patient-centered secondary outcomes, the mean total duration of treatment was 180, 106, and 85 days for the standard, rifampin-linezolid, and bedaquiline-linezolid groups, respectively. Participants in the eight-week initial treatment groups reported lower anxiety related to the regimen and higher motivation to take treatment. Incidences of respiratory disability, serious adverse events, and death at the end of the study were not significantly different between groups. This study suggests that there may be value in shifting the tuberculosis management strategy from a 24-week regimen to a shorter regimen.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antituberculosis treatmentBedaquilineBedaquiline-linezolidchronic diseaseinfectious diseaselinezolidmycobacterium tuberculosispulmonologyrespirologytuberculosis
Previous Post

#VisualAbstract: A closed-loop system of insulin delivery is superior in glycemic control for children with type 1 diabetes

Next Post

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

RelatedReports

Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Food compounds associated with disease activity in inflammatory bowel disease 

June 25, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 23, 2025

June 23, 2025
Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines
Cardiology

Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms

June 19, 2025
Next Post
Proton radiotherapy may be effective for refractory pituitary adenomas

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
  • The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.